Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial
Latest Information Update: 08 May 2023
At a glance
- Drugs Amoxicillin (Primary) ; Rabeprazole (Primary) ; Clarithromycin; Metronidazole
- Indications Helicobacter pylori infections
- Focus Therapeutic Use
- 03 May 2023 Results assessing to compare the efficacy of 14-day High-dose dual therapy by comparing it to 14-day rabeprazole-containing hybrid therapy (HT) and to investigate the host and bacterial factors predicting the treatment outcomes of eradication therapies, published in the Infectious Diseases and Therapy.
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.
- 23 Dec 2021 Planned End Date changed from 31 Dec 2021 to 28 Feb 2022.